Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 300

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 300
---
 based on existing or novel Current Procedural Terminology (CPT) and/or PLA codes;                                 |
| ● | Government and private payors, with whom DiamiR plans to initiate a dialog and to submit relevant applications as soon as feasible; and          |
| ● | Patients and at-risk individuals who pay co-payments, deductibles and other amounts that DiamiR is unable to collect from their health insurers. |

After this offering, DiamiR plans to expand its
team with reimbursement and regulatory experts, and DiamiR will work diligently towards securing reimbursement based on current regulations.
DiamiR plans on creating a clinical dossier compromised of peer-review publications on the following 4 key areas:

| 1. | Analytical Validation-The assay correctly and reproducibly tests for specific analytes / targets                                                                              |
| 2. | Clinical Validation- The assay’s target analytes rule-in or rule-out a disease                                                                                                |
| 3. | Clinical utility-The test results in changes with physician behavior or patient treatment                                                                                     |
| 4. | Cost-effectiveness and economic health benefits - The test saves the healthcare system money, either by reducing unnecessary treatment, improving outcomes or other measures. |

A robust clinical dossier is a critical tool for
successful reimbursement discussions with payors. DiamiR’s management team has experience with, and understands the process, and
will focus its efforts to gain insurance coverage in a timely manner.

Accurate early diagnostics of AD will improve
effectiveness of future cost of care for AD. The current cost of care for AD and AD related issues is estimated to be around $345B annually
and is expected to reach $1Trillion by 2050.

<div align='center'>*https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf

160</div>

Strategies and products designed for early identification
of AD are key to reducing the financial burden of AD to payors, caregivers and families of those impacted by this disease. Thus, the use
of CogniMIR and DiamiR’s other future tests align with payors’ goals to improve the affordability and efficacy
of diagnosis and treatment for AD.

Other supportive publications on cost effectiveness
of early intervention include:

“Evaluation of the Cost-effectiveness of
Drug Treatment for Alzheimer Disease in a Simulation Model That Includes Caregiver and Societal Factors.” Ito et. al. JAMA Netw
Open. 2021 Oct; 4(10): e